Joflupaani (123i) Rotop

Ioflupane, the active ingredient in Joflupaani (123i) Rotop, is a radiopharmaceutical presented as an intravenous injection for intravenous use. It is employed to image dopamine transporters and assess dopaminergic neuronal integrity in patients with suspected Parkinsonian syndromes and other movement disorders.

GNH USA supplies Joflupaani (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ioflupane is used in diagnostic imaging of the dopaminergic system, particularly for conditions affecting dopamine transporters. - Parkinsonian syndromes: enables visualization of dopamine transporter loss to support diagnosis. - Differential diagnosis of movement disorders: helps distinguish Parkinson's disease from other tremor or rigidity disorders. - Research investigations: provides a tool for studying dopaminergic neuronal integrity in clinical studies.

Ioflupane is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain during or after the procedure. - Nausea: transient feeling of queasiness. - Dizziness: occasional light‑headedness post‑injection. - Injection site pain: mild discomfort at the venipuncture site. - Mild hypotension: temporary drop in blood pressure. - Flushing: brief skin reddening.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Acute pulmonary edema: rare respiratory distress. - Cardiac arrhythmia: uncommon irregular heart rhythm. - Severe hypotension: marked blood pressure fall requiring intervention.

When using Ioflupane, clinicians should consider several safety measures. - Pregnancy: avoid use unless clearly needed, as fetal safety is unknown. - Breastfeeding: discontinue nursing or discontinue the drug, because the radiopharmaceutical may be excreted in milk. - Renal impairment: assess kidney function, as reduced clearance may affect distribution. - Concomitant dopamine‑affecting drugs: be aware that substances such as cocaine or amphetamines can alter imaging results. - Radiation exposure: limit repeated scans and follow local radiation safety guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with other agents that influence dopamine transport or radiation exposure.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may cause cumulative radiation dose. - Cocaine or amphetamines: can competitively inhibit DAT binding, compromising image quality. - MAO‑B inhibitors: may alter tracer distribution.

Moderate Interactions (Monitor Closely): - Antihistamines: may cause mild changes in tracer uptake. - SSRIs or SNRIs: potential modest effect on DAT availability. - Beta‑blockers: possible influence on cardiovascular response during imaging.